Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Staphylococcal Skin Infection Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage

NCT02024867
View directory record Official record
Conditions
Skin Disease, Bacterial, Abscess
Interventions
Trimethoprim-Sulfamethoxazole
Drug
Lead sponsor
Lucy Holmes, MD
Other
Eligibility
3 Months to 17 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional

Study of Wound Packing After Superficial Skin Abscess Drainage

NCT00746109
View directory record Official record
Conditions
Abscess, Skin Diseases, Infectious, Boils, Furuncle, Carbuncle, Folliculitis, Cellulitis, Wounds
Interventions
Wound packing, NoPacking
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
1 Year to 24 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 3, 2011 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess

NCT02334384
View directory record Official record
Conditions
Furunculosis
Interventions
Antimicrobial TheraGauze
Biological
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed Phase 4 Interventional

Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence

NCT02566928
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Recurrence, Staphylococcal Skin Infections, Antibiotic Resistance
Interventions
2% mupirocin ointment, Chlorhexidine wash, Hygiene protocol
Drug · Other · Behavioral
Lead sponsor
Clinical Directors Network
Network
Eligibility
7 Years to 70 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Brooklyn, New York • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Individualized vs. Household MRSA Decolonization

NCT01814371
View directory record Official record
Conditions
Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
Drug · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues

NCT04666532
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

Prevention of Recurrent Infections Caused by Community Acquired Staphylococcus Aureus (CA-SA) in Children

NCT00901316
View directory record Official record
Conditions
Community-Acquired Staphylococcus Aureus
Interventions
Routine Measures Group, Bleach Bath Group (Bleach plus routine measures)
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Months to 18 Years
Enrollment
987 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

NCT02814916
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Interventions
Dalbavancin, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 17 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

NCT00626795
View directory record Official record
Conditions
Impetigo, Secondarily Infected Traumatic Lesions
Interventions
TD1414 2% cream, Bactroban® (mupirocin) 2% cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
2 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections

NCT00948142
View directory record Official record
Conditions
Skin Diseases, Bacterial
Interventions
CEM-102, Linezolid
Drug
Lead sponsor
Arrevus Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Chula Vista, California • La Mesa, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated Phase 4 Interventional Results available

Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage

NCT01673061
View directory record Official record
Conditions
Abscess
Interventions
Lidocaine, Vapocoolant
Drug
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00424190
View directory record Official record
Conditions
Bacterial Infections
Interventions
IV Vancomycin plus IV Aztreonam, Ceftaroline
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
698 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
Dothan, Alabama • Long Beach, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections

NCT00423657
View directory record Official record
Conditions
Bacterial Infections
Interventions
ceftaroline, vancomycin plus aztreonam, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
17
States / cities
Buena Park, California • Hawaiian Gardens, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional

A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection

NCT00560599
View directory record Official record
Conditions
Methicillin Resistant Staphylococcus Aureus Skin Infections
Interventions
mupirocin and chlorhexidine, household cleaning and disinfection, mupirocin, chlorhexidine, & household cleaning/disinfection
Drug · Behavioral
Lead sponsor
loren g miller
Other
Eligibility
1 Month and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
6
States / cities
Anaheim, California • Bellflower, California • Harbor City, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 4 Interventional Results available

Staph Household Intervention for Eradication (SHINE)

NCT02572791
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus, MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions
Chlorhexidine, Mupirocin, Household cleaning
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 18 Years
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 11, 2026, 8:23 AM EDT
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02052388
View directory record Official record
Conditions
Skin Infection, Bacterial Infection
Interventions
Daptomycin, Brilacidin
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional Results available

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

NCT00758862
View directory record Official record
Conditions
Secondarily Infected Traumatic Lesions (SITL), Impetigo
Interventions
2% TD1414 Cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees

NCT01105767
View directory record Official record
Conditions
Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections
Interventions
Chlorhexidine gluconate, Supplemental training, education and hygiene
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 42 Years · Male only
Enrollment
30,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 2 Interventional

A Study for Patients With Complicated Skin and Skin Structure Infections

NCT00514527
View directory record Official record
Conditions
Staphylococcal Skin Infections, Wounds and Injuries, Abscess, Cellulitis, Streptococcal Infections
Interventions
oritavancin
Drug
Lead sponsor
Targanta Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
33
States / cities
Mobile, Alabama • Anaheim, California • Buena Park, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2008 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Not applicable Interventional Results available

The Natural History of Community-Associated MRSA Infections and Decolonization Strategies

NCT00513799
View directory record Official record
Conditions
Abscesses, Furunculosis, Staphylococcus Aureus, Staphylococcal Skin Infections
Interventions
Mupirocin ointment, Chlorhexidine showers, Bleach baths (dilute), Intensive education on personal hygiene
Drug · Genetic · Procedure + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

NCT02115399
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Non-atopic Healthy Controls
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Denver, Colorado • Rochester, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 11, 2026, 8:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

NCT03275870
View directory record Official record
Conditions
Hidradenitis Suppurativa, Hidradenitis, Acne Inversa, Boils, Follicular Occlusion Triad, Follicular Occlusion Tetrad
Interventions
Hydroxychloroquine
Drug
Lead sponsor
Elena Gonzalez Brant, MD
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 11, 2026, 8:23 AM EDT